Inpharma Weekly

, Volume 1289, Issue 1, pp 8–8 | Cite as

Targeted CMV prophylaxis with valganciclovir viable

Clinical study
  • 3 Downloads

Keywords

Valganciclovir Oral Valganciclovir Total Lifetime Cost Adjusted Life Expectancy Minor Adverse Reaction 

Copyright information

© Adis International Ltd 2001

Personalised recommendations